Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Beclomethasone 17-Monoproprionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Beclomethasone 17-Monoproprionate is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Beclomethasone 17-Monoproprionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CK-0045
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Cytoki Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CK-0045 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : CK-0045
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Cytoki Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Intract Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease
Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Intract Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients
Details : French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : Biophytis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respi...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Biophytis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Vicore Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : C21 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Raynaud Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Vicore Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Atriva Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2020
Lead Product(s) : zapnometinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Atriva Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : H3N2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers
Details : H3N2 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 04, 2020
Lead Product(s) : H3N2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Eloxx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Details : ELX-02 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Genetic Diseases, Inborn.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2017
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Eloxx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Eloxx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of ELX-02 in Healthy Adults
Details : ELX-02 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Genetic Diseases, Inborn.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2017
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Eloxx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable